Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(4):CD002936.
doi: 10.1002/14651858.CD002936.

Intravenous immunoglobulins for multiple sclerosis

O Gray, G V McDonnell, R B Forbes

Intravenous immunoglobulins for multiple sclerosis

O Gray et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: From animal experiments, there is evidence to suggest that intravenous immunoglobulins can reverse some of the disease process of central nervous system demyelination. Subsequently, clinical trials of intravenous immunoglobulins have been conducted in people with multiple sclerosis (MS).

Objectives: To identify and summarise the evidence that intravenous immunoglobulins are safe and beneficial for people with MS.

Search strategy: We searched the Cochrane Multiple Sclerosis Group trials Register( January 2003) The Cochrane Central Register of Controlled Trials (The Cochrane Library issue 4, 2002), MEDLINE (January 1966 to April 2001), EMBASE (January 1988 to April 2001) and reference lists of articles. We also contacted relevant pharmaceutical companies and authors of identified trials.

Selection criteria: Randomised controlled trials of intravenous immunoglobulins for the secondary prevention of relapses and disease progression in MS.

Data collection and analysis: 913 titles and abstracts were obtained from the literature search, and we eventually identified 10 clinical trials. All reviewers agreed on the final dataset for entry into RevMan 4.1, and summarised the results. Study authors were contacted for additional information but no response was obtained.

Main results: Of 913 potential studies, 10 trials were identified with a total of 918 participants, four of which are in progress or awaiting publication. The remaining six trials were suitable for consideration by this review (344 participants). Only two trials met our protocol's inclusion criteria. The four remaining trials were excluded as they did not use outcome measures specified in our review (2 trials, 122 participants), or were of insufficient methodological quality (2 trials, 34 participants). From the two included trials (168 participants) there was a reduction in relapse rate and increased time to first relapse during treatment with intravenous immunoglobulins, but reliable disease progression outcomes were not reported, nor were magnetic resonance imaging (MRI) data available to support clinical information. There may be as many as 574 participants in ongoing or yet to be published trials.

Reviewer's conclusions: There is some evidence to support use of intravenous immunoglobulins as a preventative treatment for relapses in relapsing remitting MS, but further studies should be performed using MRI and disease progression endpoints. It may be possible to draw more robust conclusions when ongoing or recently completed trials make their data available for review. Two rigorously conducted trials with a total of 122 participants did not demonstrate a positive clinical benefit, but were excluded from this review as they employed outcome measures not specified in our protocol. Immunoglobulins were well tolerated with a less than 5% risk of adverse events in participants in included trials.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

References to studies included in this review

Achiron 1998 {published data only}
    1. Achiron A, Gabbay U, Gilad R, Hassin‐Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50(2):398‐402. - PubMed
Fazekas 1997 {published data only}
    1. Fazekas F, Strasser‐Fuchs S, Nahler G, Mamoli B for The Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo‐controlled trial of monthly intravenous immunoglobulin therapy in relapsing‐remitting multiple sclerosis. Lancet 1997;349(9052):589‐93. - PubMed
Fazekas 2008 {published data only}
    1. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, et al. Intravenous immunoglobulin in relapsing‐remitting multiple sclerosis. Neurology 2008;71:265‐71. - PubMed
Hommes 2004 {published data only}
    1. Hommes OR, Sorensen PS, Fazekas F, Maas‐Enriquez M, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo‐controlled trial. Lancet 2004;364:1149‐56. - PubMed
Lewanska 2002 {published data only}
    1. Lewanska M, Siger‐Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. European Journal of Neurology 2002;9:565‐72. - PubMed
Poehlau 2007 {published data only}
    1. Poehlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Koenig N, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Multiple Sclerosis 2007;13:1107‐17. - PubMed

References to studies excluded from this review

Noseworthy 2000 {published data only}
    1. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000;55(8):1135‐43. - PubMed
Noseworthy 2001 {published data only}
    1. Noseworthy JH, O'Brien PC, Petterson TM, Weis T, Stevens L, Peterson WK, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56(11):1514‐22. - PubMed
Sorenson 1998 {published data only}
    1. Sorenson PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50(5):1273‐81. - PubMed
Teksam 2000 {published data only}
    1. Teksam T, Tali T, Kocer B, Isik S. Qualititative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000;42(12):885‐9. - PubMed

Additional references

ABN 2005
    1. Association of British Neurologists. Guidelines for the use of intravenous immunoglobulin in neurological disease. Guidelines for the use of intravenous immunoglobulin in neurological disease. London, UK, July 2005.
Branagan 1996
    1. Branagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47(3):674‐7. - PubMed
D'Amico 2003
    1. D'Amico R, Ebers G, Filippini G, Fredrikson S, Pietrantonj C, Rice GPA, et al. Cochrane Multiple Sclerosis Group. In: The Cochrane Library. 2008, Issue 2. Chichester: Wiley‐Blackwell. Updated quarterly.
Hawkins 1999
    1. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. Journal of Neurology Neurosurgery and Psychiatry 1999;67(2):148‐52. - PMC - PubMed
Hughes 1996
    1. Hughes RA, Sharrack B. More immunotherapy for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1996;61(3):239‐41. - PMC - PubMed
INFB Group 1993
    1. The IFNB Multiple Sclerosis Study Group. Interferon beta1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology 1993;43(4):655‐61. - PubMed
Kurtzke 1983
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444‐52. - PubMed
Lefebvre 2008
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Lublin 1996
    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46(4):907‐11. - PubMed
Martinelli 2005
    1. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD002127] - DOI - PubMed
Noseworthy 1994
    1. Noseworthy JH, O'Brien PC, Engelen BGM, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theilers virus model to a randomised, double blind, placebo controlled clinical trial. Neurology 1994;57(suppl):11‐4. - PMC - PubMed
Poleman 2006
    1. Poleman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomised, placebo‐controlled trial of natalizumab for relapsing remitting multiple sclerosis. New England Journal of Medicine 2006;354(9):899‐910. - PubMed
Poser 1983
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for clinical protocol research. Annals of Neurology 1983;13(3):227‐31. - PubMed
Rodriguez 1987
    1. Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. Journal of Neuropathology and Experimental Neurology 1987;46(1):84‐95. - PubMed
Rodriguez 1990
    1. Rodriguez M, Lennon VA. Immunoglobulin promotes remyelination in the central nervous system. Annals of Neurology 1990;27(1):12‐7. - PubMed
Thornton 1993
    1. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Archives of Neurology 1993;50(2):135‐6. - PubMed

Publication types

MeSH terms

Substances